SavedAdd your journal

Journals / Meandros Medical And Dental Journal / 2026 / Volume: 27 Issue: 2

The Relationship Between PD-1 Expression and Metabolic PET/CT Rarameters of Primary Tumor in NSCLC

NSCLC' de primer tümörün metabolik PET/BT parametreleri ile PD-1 ekspresyonu arasındaki ilişki

Sibel Göksel(ADNAN MENDERES ÜNİVERSİTESİ)0000-0003-2584-1386
Ogün Bülbül(RECEP TAYYİP ERDOĞAN ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0002-4154-8801
Recep Bedir(RECEP TAYYİP ERDOĞAN ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0001-8247-3781
Sema Rakici(RECEP TAYYİP ERDOĞAN ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0002-5543-9761
Pages
—
Publication Date
2026-06-24
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this study, no relationship was found between the metabolic PET/CT parameters and PD-1 expression.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim Our study was to investigate the correlation between metabolic tumor parameters of the primary tumor and programmed cell death protein-1 (PD-1) expression of the tumor cell and the value of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) imaging in predicting the PD-1 expression in non-small cell lung cancer (NSCLC).
📊
Key Findings & Data:Materials and Methods A total of 79 patients diagnosed with NSCLC were included in this retrospective study.
💡
Conclusion & Impact:In this study, no relationship was found between the metabolic PET/CT parameters and PD-1 expression.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Immunotherapy · metabolic tumor volume · non-small cell lung cancer

Abstract

Aim Our study was to investigate the correlation between metabolic tumor parameters of the primary tumor and programmed cell death protein-1 (PD-1) expression of the tumor cell and the value of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) imaging in predicting the PD-1 expression in non-small cell lung cancer (NSCLC). Materials and Methods A total of 79 patients diagnosed with NSCLC were included in this retrospective study. PD-1 expression of tumors was determined by immunohistochemistry staining. All patients had PET/CT scans available at initial staging. The correlation between PD-1 expression of tumor cells and metabolic PET/CT parameters of the primary tumor was evaluated by Spearman correlation analysis. Whether metabolic PET/CT parameters predicted PD-1 expression was evaluated by Receiver operating characteristic (ROC) Curve analysis. Results No statistically significant relationship has been detected between the metabolic tumor parameters of the primary tumor and other clinicopathological data, or with PD-1 expression in tumor cells. Conclusion 18F-FDG uptake rate in tumor cells is a non-invasive method that indicates biomarker status in cancer patients. Clinicians use biomarkers such as PD-1 to help them decide whether to start immunotherapy in their patients. In this study, no relationship was found between the metabolic PET/CT parameters and PD-1 expression.

Özet

Amaç Çalışmamızın amacı, primer tümörün metabolik tümör parametreleri ile tümör hücresinin programlanmış hücre ölüm proteini-1 (PD-1) ekspresyonu arasındaki ilişkiyi ve küçük hücreli olmayan akciğer kanserinde (KHDAK) PD-1 ekspresyonunu tahmin etmede Flor-18 florodeoksiglukoz pozitron emisyon tomografisi/bilgisayarlı tomografi (18F-FDG PET/BT) görüntülemenin değerini araştırmaktır. Yöntemler Bu retrospektif çalışmaya KHDAK tanısı almış toplam 79 hasta dahil edildi. Tümörlerin PD-1 ekspresyonu immünohistokimya boyama ile belirlendi. Tüm hastaların başlangıç evrelemede PET/BT taramaları mevcuttu. Tümör hücrelerinin PD-1 ekspresyonu ile primer tümörün metabolik PET/BT parametreleri arasındaki korelasyon Spearman korelasyon analizi ile değerlendirildi. Metabolik PET/BT parametrelerinin PD-1 ekspresyonunu tahmin edip etmediği ROC Eğrisi analizi ile değerlendirildi. Sonuçlar Primer tümörün metabolik tümör parametreleri ve diğer klinikopatolojik veriler ile tümör hücresinin PD-1 ekspresyonu arasında istatistiksel olarak anlamlı bir ilişki saptanmamıştır. Sonuç Tümör hücrelerindeki 18F-FDG tutulum oranı, kanser hastalarında biyobelirteç durumunu gösteren invaziv olmayan bir yöntemdir Klinisyenler, hastalarına immünoterapi başlama kararını PD-1 gibi biyobelirteçleri kullanarak verirler. Bu çalışmada, metabolik PET/BT parametreleri ile PD-1 ekspresyonu arasında bir ilişki bulunamadı.

🔖

Cite This Article

Göksel, S., Bülbül, O., Bedir, R., Rakici, S. (2026). The Relationship Between PD-1 Expression and Metabolic PET/CT Rarameters of Primary Tumor in NSCLC. Meandros Medical And Dental Journal, Volume: 27 Issue: 2. https://doi.org/10.69601/meandrosmdj.1827430

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (22)

  1. Vekens K, Everaert H, Neyns B, Ilsen B, Decoster L. The Value of 18F-FDG PET/CT in Predicting the Response to PD-1 Blocking Immunotherapy in Advanced NSCLC Patients with High-Level PD-L1 Expression. Clin Lung Cancer 2021;22:432-440.
  2. R. Siegel, D. Naishadham, A. Jemal. Cancer statistics, 2012. CA: Cancer J Clin 2012;62:10-29.
  3. Wu X, Huang Y, Zhao Q, Wang L, Song X, Li Y, et al. PD-L1 expression correlation with metabolic parameters of FDG PET/CT and clinicopathological characteristics in non-small cell lung cancer. EJNMMI Res 2020;10:51.
  4. Zhang L, Sun L, Zhou Y, Yu J, Lin Y, Wasan HS, et al. Association of Survival and Immune-Related Adverse Events With Anti-PD-1/PD-L1 and Anti-CTLA-4 Inhibitors, Alone or Their Combination for the Treatment of Cancer: A Systematic Review and Meta-Analysis of 13 Clinical Trials. Front Oncol 2021;11:575457.
  5. Hashimoto K, Kaira K, Yamaguchi O, Shiono A, Mouri A, Miura Y, et al. Visual Assessment of 18F-FDG Uptake on PET to Predict Survival Benefit to PD-1 Blockade in Non-Small Cell Lung Cancer. Clin Nucl Med 2022;47:108-116.
  6. Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer 2019;18:10.
  7. Jiang M, Sun D, Guo Y, Guo Y, Xiao J, Wang L, et al. Assessing PD-L1 Expression Level by Radiomic Features From PET/CT in Nonsmall Cell Lung Cancer Patients: An Initial Result. Acad Radiol 2020;27:171-179.
  8. Jadvar H, Alavi A, Gambhir SS. 18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization. J Nucl Med 2009;50:1820–7.
  9. Arslan E, Çermik TF, Trabulus FDC, Talu ECK, Başaran Ş. Role of 18F-FDG PET/CT in evaluating molecular subtypes and clinicopathological features of primary breast cancer. Nucl Med Commun 2018;39:680-690.
  10. Lv Z, Fan J, Xu J, Wu F, Huang Q, Guo M, et al. Value of 18F-FDG PET/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patients. Eur J Nucl Med Mol Imaging 2018;45:735-750.
  11. Kaira K, Kuji I, Kagamu H. Value of 18F-FDG-PET to predict PD-L1 expression and outcomes of PD-1 inhibition therapy in human cancers. Cancer Imaging 2021;21:11.
  12. Seol HY, Kim YS, Kim SJ. Diagnostic test accuracy of 18F-FDG PET/CT for prediction of programmed death ligand 1 (PD-L1) expression in solid tumours: a meta-analysis. Clin Radiol 2021;76:863.e19-863.
  13. Chen R, Zhou X, Liu J, Huang G. Relationship between the expression of PD-1/PD-L1 and 18F-FDG uptake in bladder cancer. Eur J Nucl Med Mol Imaging 2019;46:848-854.
  14. Park Y, Koh J, Na HY, Kwak Y, Lee KW, Ahn SH, et al. PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs. Cancer Res Treat 2020;52:661-670.
  15. Park Y, Seo AN, Koh J, Nam SK, Kwak Y, Ahn SH, et al. Expression of the immune checkpoint receptors PD-1, LAG3, and TIM3 in the immune context of stage II and III gastric cancer by using single and chromogenic multiplex immunohistochemistry. Oncoimmunology 2021;10:1954761.
  16. Teixidó C, Karachaliou N, González-Cao M, Morales-Espinosa D, Rosell R. Assays for predicting and monitoring responses to lung cancer immunotherapy. Cancer Biol Med 2015;12(2):87-95.
  17. Schmidt LH, Kümmel A, Görlich D, Mohr M, Bröckling S, Mikesch JH, et al. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups. PLoS One 2015 27;10:e0136023.
  18. He Y, Rozeboom L, Rivard CJ, Ellison K, Dziadziuszko R, Yu H, et al. PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes. Med Sci Monit 2017;23:1208-1216.
  19. Takada K, Toyokawa G, Tagawa T, Kohashi K, Akamine T, Takamori S, et al. Association Between PD-L1 Expression and Metabolic Activity on 18F-FDG PET/CT in Patients with Small-sized Lung Cancer. Anticancer Res 2017;37:7073-7082.
  20. Gu Y, Tang YY, Wan JX, Zou JY, Lu CG, Zhu HS, et al. Sex difference in the expression of PD-1 of non-small cell lung cancer. Front Immunol 2022;13:1026214.
  21. Lafuente-Sanchis A, Zúñiga Á, Estors M, Martínez-Hernández NJ, Cremades A, Cuenca M, et al. Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer. Clin Lung Cancer 2017;18:e109-e116.
  22. Zhang M, Wang D, Sun Q, Pu H, Wang Y, Zhao S, et al. Prognostic significance of PD-L1 expression and 18F-FDG PET/CT in surgical pulmonary squamous cell carcinoma. Oncotarget 2017;8:51630-51640.